Overview
Alzheimer's disease (AD) poses a significant public health concern, exhibiting notable variations in prevalence, incidence, and outcomes among different ethnic groups in Israel. However, the underlying biological basis for these disparities remains largely unknown. Blood biomarkers, such as p-Tau and beta-Amyloid, hold potential in identifying individuals at an increased risk and progression of Alzheimer's disease. Nevertheless, there is evidence suggesting variations in biomarker levels across different ethnic groups. Unfortunately, data regarding these differences in Israel are scarce.
Project Details
Our pilot project aims to address this knowledge gap by including a diverse sample to investigate ethno-racial variations in AD biomarkers, specifically focusing on p-tau181, within three distinct ethnic groups in Israel. We will also explore whether any demographic or clinical features contribute to these differences and examine their correlation with cognitive test performance. The project will include 90 participants with dementia: from the three main ethnic groups including Arabs, Ashkenazi Jews, and Sephardic Jews; 20 participants suffering from dementia and 10 healthy controls from each group. Blood samples drawn will be tested for p-tau181 using a standardized SIMOA assay. The levels of p-Tau and beta will be compared between groups, correlated to cognitive performance measures, and any demographic or clinical factors that may contribute to observed differences will be investigated. Statistical analysis will include descriptive statistics, ANOVA, multivariable linear regression analysis.
This pioneering study will be the first in Israel to explore the sociobiological factors that contribute to ethno-racial disparities in AD risk and biomarkers across diverse ethnic groups. This pilot study will provide important preliminary data for a larger study on ethnic disparities in Alzheimer's disease risk and biomarkers in Israel and could contribute significantly to creating validated, normalized tests that will ensure equitable access to early detection, intervention, and care for all ethnicities in Israel.
Members involved
Featured Collaborators
